Patterns of corticosteroid use among remdesivir and matched patients and associated clinical outcomes in hospitalized COVID-19 patients

被引:0
|
作者
Papic, Ivan [1 ]
Bistrovic, Petra [2 ]
Keres, Tatjana [3 ]
Hadziabdic, Maja Ortner [4 ]
Lucijanic, Marko [5 ,6 ,7 ]
机构
[1] Univ Hosp Dubrava, Pharm Dept, Zagreb, Croatia
[2] Univ Hosp Dubrava, Cardiol Dept, Zagreb, Croatia
[3] Univ Hosp Dubrava, Intens Care Dept, Zagreb, Croatia
[4] Univ Zagreb, Fac Pharm & Biochem, Ctr Appl Pharm, Zagreb, Croatia
[5] Univ Hosp Dubrava, Hematol Dept, Av Gojka Suska 6, Zagreb, Croatia
[6] Univ Zagreb, Sch Med, Internal Med Dept, Zagreb, Croatia
[7] Univ Zagreb, Sch Med, Zagreb 10000, Croatia
关键词
Remdesivir; corticosteroids; prognosis; dexamethasone; methylprednisolone; prednisone;
D O I
10.1080/14656566.2024.2320255
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
IntroductionWe aimed to investigate patterns of corticosteroid use and their relationship with remdesivir use and clinical outcomes in a large real-life cohort of COVID-19 patients treated in a tertiary-level institution.MethodsWe retrospectively analyzed a total of 1558 severe and critical COVID-19 patients, including 779 patients treated with remdesivir and 779 matched control patients.ResultsA total of 167 (10.7%) patients received none, 710 (45.6%) low, 539 (34.6%) high, and 142 (9.1%) very high corticosteroid doses. Patients treated with remdesivir had significantly longer exposure to corticosteroids, received higher average and maximal daily doses, and cumulative corticosteroid doses. In the multivariate analysis remdesivir use, lower cumulative comorbidity burden, higher severity of COVID-19 symptoms, and mechanical ventilation were recognized as mutually independent predictors of the use of higher corticosteroid doses. Higher corticosteroid doses were associated with significantly increased mortality.Among non-remdesivir treated patients, there was a U-shaped relationship between maximal daily corticosteroid dose and mortality. Among remdesivir treated patients gradual increase in mortality with increasing corticosteroid doses was observed.ResultsA total of 167 (10.7%) patients received none, 710 (45.6%) low, 539 (34.6%) high, and 142 (9.1%) very high corticosteroid doses. Patients treated with remdesivir had significantly longer exposure to corticosteroids, received higher average and maximal daily doses, and cumulative corticosteroid doses. In the multivariate analysis remdesivir use, lower cumulative comorbidity burden, higher severity of COVID-19 symptoms, and mechanical ventilation were recognized as mutually independent predictors of the use of higher corticosteroid doses. Higher corticosteroid doses were associated with significantly increased mortality.Among non-remdesivir treated patients, there was a U-shaped relationship between maximal daily corticosteroid dose and mortality. Among remdesivir treated patients gradual increase in mortality with increasing corticosteroid doses was observed.ConclusionPatterns of corticosteroid use differ regarding the use of remdesivir and may moderate its association with survival among severe and critical COVID-19 patients.
引用
收藏
页码:215 / 222
页数:8
相关论文
共 50 条
  • [41] Specific adverse outcomes associated with selective serotonin reuptake inhibitors use in COVID-19 patients might be potentiated by remdesivir use
    Papic, Ivan
    Bistrovic, Petra
    Krecak, Ivan
    Hadziabdic, Maja Ortner
    Lucijanic, Marko
    JOURNAL OF PSYCHOPHARMACOLOGY, 2024, 38 (04) : 395 - 403
  • [42] Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19: A prospective randomised study
    Mahajan, Lakshmi
    Singh, A. P.
    Gifty
    INDIAN JOURNAL OF ANAESTHESIA, 2021, 65 (13) : S41 - S46
  • [43] Clinical Outcomes and Survival Analysis of Remdesivir as a Treatment Option for Moderate to Severe COVID-19 Patients
    Aboelsaad, Iman
    Ashmawy, Rasha
    Mahrous, Doaa
    Sharaf, Sandy
    Aly, Shahinda
    Abdullatif, Sara
    Fakhry, Ayat
    Hassan, Basma
    Khamis, Dalia
    Aldakhs, Alaa
    Kamal, Ehab
    COVID, 2022, 2 (12): : 1758 - 1767
  • [44] Evaluation of Remdesivir to the outcomes of hospitalized patients with COVID-19 infection in a tertiary-care hospital in southern India
    Alexander, Hanna
    Gunasekaran, Karthik
    John, Jisha Sara
    Zacchaeus, Naveena Gracelin Princy
    Samuel, Prasanna
    Jasmine, Sudha
    Christopher, Devasahayam Jesudas
    Pichamuthu, Kishore
    Rupali, Priscilla
    JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, 2023, 17 (03): : 304 - 310
  • [45] Greek Remdesivir Cohort (GREC) Study: Effectiveness of Antiviral Drug Remdesivir in Hospitalized Patients with COVID-19 Pneumonia
    Petrakis, Vasilis
    Rapti, Vasiliki
    Akinosoglou, Karolina
    Bonelis, Constantinos
    Athanasiou, Kalomoira
    Dimakopoulou, Vasiliki
    Syrigos, Nikolaos K.
    Spernovasilis, Nikolaos
    Trypsianis, Grigoris
    Marangos, Markos
    Gogos, Charalambos
    Papazoglou, Dimitrios
    Panagopoulos, Periklis
    Poulakou, Garyfallia
    MICROORGANISMS, 2022, 10 (10)
  • [46] Optimal Timing of Remdesivir Initiation in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Administered With Dexamethasone
    Wong, Carlos K. H.
    Lau, Kristy T. K.
    Au, Ivan C. H.
    Xiong, Xi
    Chung, Matthew S. H.
    Lau, Eric H. Y.
    Cowling, Benjamin J.
    CLINICAL INFECTIOUS DISEASES, 2022, 75 (01) : E499 - E508
  • [47] Remdesivir for Hospitalized COVID-19 Patients in the United States: Optimization of Health Care Resources
    Lianne Barnieh
    Rachel Beckerman
    Sushanth Jeyakumar
    Alice Hsiao
    James Jarrett
    Robert L. Gottlieb
    Infectious Diseases and Therapy, 2023, 12 : 1655 - 1665
  • [48] Remdesivir Use Compared With Supportive Care in Hospitalized Patients With Severe COVID-19: A Single-Center Experience
    Kalligeros, Markos
    Tashima, Karen T.
    Mylona, Evangelia K.
    Rybak, Natasha
    Flanigan, Timothy P.
    Farmakiotis, Dimitrios
    Beckwith, Curt G.
    Sanchez, Martha
    Neill, Marguerite
    Johnson, Jennie E.
    Garland, Joseph M.
    Aung, Su
    Byrd, Katrina M.
    O'Brien, Thomas
    Pandita, Aakriti
    Aridi, Jad
    Gil, Raul Macias
    Larkin, Jerome
    Shehadeh, Fadi
    Mylonakis, Eleftherios
    OPEN FORUM INFECTIOUS DISEASES, 2020, 7 (10):
  • [49] Remdesivir Use in Patients Requiring Mechanical Ventilation due to COVID-19
    Lapadula, Giuseppe
    Bernasconi, Davide Paolo
    Bellani, Giacomo
    Soria, Alessandro
    Rona, Roberto
    Bombino, Michela
    Avalli, Leonello
    Rondelli, Egle
    Cortinovis, Barbara
    Colombo, Enrico
    Valsecchi, Maria Grazia
    Migliorino, Guglielmo Marco
    Bonfanti, Paolo
    Foti, Giuseppe
    OPEN FORUM INFECTIOUS DISEASES, 2020, 7 (11):
  • [50] Remdesivir for Hospitalized COVID-19 Patients in the United States: Optimization of Health Care Resources
    Barnieh, Lianne
    Beckerman, Rachel
    Jeyakumar, Sushanth
    Hsiao, Alice
    Jarrett, James
    Gottlieb, Robert L.
    INFECTIOUS DISEASES AND THERAPY, 2023, 12 (06) : 1655 - 1665